SNSE Sensei Biotherapeutics, Inc.

Sensei is a clinical-stage immunotherapy company committed to the discovery and development of next-generation therapies for the treatment of cancer. Its proprietary ImmunoPhage? platform, leveraging the self-adjuvanted and highly immunogenic properties of engineered bacteriophage, allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response. Sensei is developing a library of ImmunoPhage targeting multiple tumor-associated antigens utilizing its proprietary platform and GMP manufacturing facility to treat patients using a personalized, yet off the shelf cocktail approach. Senseiís pipeline includes its lead product candidate, SNS-301, which is currently being evaluated in combination with the PD-1 inhibitor, pembrolizumab, for the treatment of squamous cell carcinoma of the head and neck. Additional preclinical programs include SNS-401 for the treatment of Merkel cell carcinoma and a human monoclonal antibody program targeting the immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation.

As of 09/30/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/04/2021
Outstanding shares:  30,720,291
Average volume:  40,973
Market cap:   $48,845,263
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BNDK2Q7
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.35
PS ratio:   0.00
Return on equity:   -30.47%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy